Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › About

About the Incretin Atlas

A living, openly licensed database of trial results for GLP-1 receptor agonists, dual and triple agonists and amylin analogues, with a primary source and a verbatim quote behind every number.

Launched 13 October 2026 · data cut 12 November 2026 · page built 16 November 2026 · 57 molecules · 206 trial arms (99 verified against full text, 1 seed) · 15 cardiovascular outcome trials · 552 registered trials

Who

The atlas is built and edited by Medical Adviser's Group (MAG), a medical-communication and evidence agency. Editor responsible: Yakov Pakhomov, MD, PhD, Medical Director. Contact: yakov@mdwrt.com (yakov@mdwrt.com).

MAG provides medical-communication and evidence services to pharmaceutical companies, including manufacturers of medicines shown in the atlas. See Independence and funding.

What the atlas is

A database of records, not a text. Each record is one trial arm, population, duration, estimand, value, primary source and verification status. The main page draws interactive maps from the database; the molecule pages and trial pages show the same records as plain tables with stable URLs, so they can be cited and linked. The whole site is regenerated from the database on every update.

Scope

Method and update rules

Update pipeline

  1. Collect. PubMed (daily monitoring), ClinicalTrials.gov (weekly sweep: status changes, new trials, posted results), company press releases, congresses (EASD, ADA, ObesityWeek, ESC), regulators (FDA, EMA, national registers).
  2. Extract. Two independent LLM extractions under the SR Workbench protocol; every value is stored with a verbatim quote and its location in the source.
  3. Verify. Discrepancies between the two extractions, and every new record, go to a review queue approved by a human editor; record status moves from «seed» to «verified».
  4. Publish. Maps and pages are rebuilt, an entry is added to the update feed, subscribers receive an e-mail. Data snapshots are deposited on Zenodo.

Editorial rules

Corrections and how to report an error

Every value links to its primary source. If you find a discrepancy, a missing trial or an outdated status, write to yakov@mdwrt.com with the page URL, the value in question and the source. Corrections from any reader, manufacturers included, go through the same review queue as new data; accepted corrections appear in the update feed with the date. Readers can also attach a paper, poster or slides through the help-wanted list.

Independence and funding

The atlas is developed by Medical Adviser's Group and funded from MAG's own resources. No pharmaceutical company funds, reviews or approves its content, and no company sees data before publication. MAG provides medical-communication and evidence services to pharmaceutical companies, including manufacturers of medicines shown here; for this reason every value carries a link to its primary source and a verbatim quote, and corrections from any reader go through the same editorial process. The atlas is not an advertisement of medicinal products; data belong to the authors of the cited works.

Data and licence

The database (CSV and JSON) is deposited on Zenodo: DOI 10.5281/zenodo.23473913 (concept DOI, all versions; latest snapshot 19 October 2026). Data are released under CC BY 4.0: reuse with attribution to Medical Adviser's Group and to the primary publications. Page text and figures may be quoted with attribution.

How to cite

Medical Adviser's Group. Incretin Atlas: a living evidence map of GLP-1, dual and triple agonists. https://docs.mdwrt.app/infographics/incretin-atlas/ Data cut 12 November 2026. Data: doi:10.5281/zenodo.23473913.
BibTeX
@misc{incretin_atlas_2026, title = {Incretin Atlas: a living evidence map of GLP-1, dual and triple agonists}, author = {{Medical Adviser's Group}}, year = {2026}, howpublished = {\url{https://docs.mdwrt.app/infographics/incretin-atlas/}}, note = {Data cut 12 November 2026; data: doi:10.5281/zenodo.23473913} }

Please cite the atlas when you reuse its figures or numbers, and cite the primary publication for any single result.

Recent updates

Full feed with the list of changes: main page, Updates.

For search engines and language models

All pages are static HTML with tables and schema.org markup (Dataset, MedicalTrial, ScholarlyArticle). Machine-readable indexes: sitemap.xml, llms.txt (page list) and llms-full.txt (all molecule and trial records as plain text). Crawling by search engines and AI crawlers is allowed (robots.txt).